共查询到20条相似文献,搜索用时 0 毫秒
1.
《Journal of the American Medical Directors Association》2020,21(8):1058-1064.e6
ObjectiveTo determine risks of embolic events, bleeding, and mortality with direct oral anticoagulants (DOACs) vs warfarin in people with atrial fibrillation (AF) and dementia.DesignNew-user retrospective cohort study using The Health Improvement Network database.Setting and ParticipantsA population-based sample comprising people with AF and dementia prescribed DOACs or warfarin from August 2011 to September 2017.MethodsRisk of ischemic stroke (IS), ischemic stroke/transient ischemic attack/systemic embolism (IS/TIA/SE), all-cause mortality, intracranial bleeding (ICB), gastrointestinal bleeding (GIB), and other bleeding were compared for DOACs vs warfarin using propensity score–adjusted Poisson regression. Incidence rate ratios (IRRs) and absolute risk differences (ARDs) were calculated.ResultsOverall, 2399 people with AF and dementia initiated DOACs (42%) or warfarin (58%). Before propensity score adjustment, patients who initiated DOACs were older and had more comorbidities. After adjustment, DOAC initiators demonstrated similar risks of IS, TIA, or SE; IS alone; and other bleeding but reduced ICB risk (IRR 0.27, 95% CI 0.08, 0.86; ARD −5.2, 95% CI –6.5, −1.0, per 1000 person-years) compared with warfarin. Increased risk of GIB (IRR 2.11, 95% CI 1.30, 3.42; ARD 14.8, 95% CI 4.0, 32.4, per 1000 person-years) and all-cause mortality (IRR 2.06, 95% CI 1.60, 2.65; ARD 53.0, 95% CI 30.2, 82.8, per 1000 person-years) were observed in DOAC initiators compared with warfarin.Conclusions and ImplicationsAmong people with AF and dementia, initiating treatment with DOACs compared with warfarin was associated with similar risks of IS, TIA, or SE and IS alone. DOAC-treated patients demonstrated reduced ICB risk but increased GIB and all-cause mortality risks. We cannot exclude the possible impact of residual confounding from channeling of DOACs toward older and sicker people, particularly for the outcome of all-cause mortality. Further safety data are urgently needed to confirm findings. 相似文献
2.
《Journal of the American Medical Directors Association》2023,24(8):1233-1239.e26
ObjectiveTo evaluate the efficacy and safety of oral anticoagulants for older adult patients with atrial fibrillation (AF).DesignPairwise and network meta-analyses.Setting and ParticipantsPatients with AF aged ≥75 years.MethodsPubMed, Embase, and the Cochrane library were searched for published randomized controlled trials and adjusted observational studies evaluating the use of a non–vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonist, or antiplatelet drug for the prevention of stroke. The primary efficacy and safety outcomes were the composite of stroke and systemic embolism (SSE) and major bleedings.ResultsThis study included 38 studies enrolling 1,022,908 older adult patients with AF. Results from pairwise meta-analyses showed that NOACs were superior to warfarin for all outcomes, except that dabigatran increased the risk of gastrointestinal (GI) bleedings. Aspirin was associated with a higher risk of SSE and ischemic stroke than warfarin or NOACs. Results of network meta-analyses indicated that apixaban significantly reduced the risk of SSE, major bleedings, and GI bleedings than warfarin, rivaroxaban, and dabigatran. Apixaban, edoxaban, rivaroxaban, and dabigatran reduced the risk of ischemic stroke and intracranial bleeding compared to warfarin. Dabigatran showed lower risk of all-cause mortality than warfarin and of intracranial bleeding than rivaroxaban.Conclusions and ImplicationsNOACs are of at least equal efficacy, or even superior to warfarin. The safety profile of individual NOAC agents was significantly different, as apixaban performs better than the other oral anticoagulants in reducing major bleeding and GI bleeding, whereas dabigatran increased the risk of GI bleeding. 相似文献
3.
《Journal of the American Medical Directors Association》2021,22(10):2190-2195
ObjectivesAngiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARB) have shown antiarrhythmic effects that are useful as part of the upstream therapy for atrial fibrillation (AF), both for primary and secondary prevention. Nevertheless, the potential prognosis value of these drugs in terms of mortality and major cardiovascular events is unclear, especially in older population with AF. Scientific evidence is scarce in this population and shows contradictory results. The aim of this study was to assess the potential benefit of ACEi and ARB in terms of mortality and major cardiovascular outcomes (hospitalization for heart failure, acute myocardial infarction and stroke) in older patients with AF, based on a real-world data analysis.DesignObservational: analysis of a retrospective registry.Settings and ParticipantsThe study included 9365 patients of 75 years or older diagnosed with AF, from CardioCHUVI-AF_75 registry: ClinicalTrials.gov Identifier: NCT04364516. Date of registration: November 26, 2018.MethodsWe performed propensity score matching techniques to obtain 2 comparable groups of 3601 patients with and without ACEi or ARB treatment. We compared survival and cardiovascular outcomes in both groups of patients using Cox proportional hazards models.ResultsWe did not find significant differences in terms of survival between using or not using ACEi or ARB for the older population (hazard ratio for mortality: 0.959, 95% confidence interval 0.872–1.054). There were no significant differences regarding cardiovascular major events between the 2 groups.Conclusions and ImplicationsTreatment with ACEi or ARB did not improve outcomes in terms of survival and cardiovascular events in older patients with AF. These results should prompt the conduct of randomized clinical trials specifically in the older AF patient population to robustly address this issue. 相似文献
4.
5.
《Journal of the American Medical Directors Association》2014,15(8):576-581
ObjectivesAtrial fibrillation (AF) and chronic obstructive pulmonary disease (COPD) are 2 common morbidities and often coexist. Studies have shown that COPD is a risk factor for cardiovascular disease, but the characteristics in patients with COPD and AF, as well as the impact of COPD on the outcomes of AF were lacking. The aim of present study was to analyze the clinical characteristics and to evaluate the association of COPD with 1-year outcomes in patients with AF.DesignLongitudinal observational study.ParticipantsA total of 1975 consecutive patients with AF were registered. Patients were divided into COPD group and non-COPD group according to whether AF coexisted with COPD.MeasurementsOutcome measures included all-cause mortality, stroke, and major adverse events (MAE) during 1-year follow-up.ResultsA group of 227 (11.5%) patients had concomitant COPD. Compared with non-COPD patients, patients with COPD were older and tended to have other coexisting cardiovascular morbidities, and had a significantly higher percentage of smoking history. Anticoagulation with warfarin was adopted by only a few patients both with and without COPD. During 1-year follow-up, the all-cause mortality and major adverse event rate in the COPD group were significantly higher than that of non-COPD group (26.9% vs 12.3%, P < .001 and 25.6% vs 19.1%, P = .027, respectively), whereas the incidence of stroke in the 2 groups was comparable (7.9% vs 7.4%, P = .788). Moreover, the cause-specific mortality between the 2 groups was comparable. After multivariate adjustments, COPD was still an independent risk factor for both1-year all-cause mortality [hazard rate (HR) = 1.491, 95% confidence interval (CI) 1.110–2.002, P = .008] and cardiovascular mortality (HR = 1.595, 95% CI 1.071–2.376, P = .022), but not a risk factor for stroke (HR = 0.879, 95% CI 0.527–1.464, P = .620).ConclusionsAnticoagulation treatment is inadequate in patients with AF and COPD. The presence of COPD in patients with AF is an independent risk factor for 1-year all-cause mortality and cardiovascular mortality but not a risk factor for stroke. 相似文献
6.
目的:探讨高血压患者心房颤动(AF)发作与血同型半胱氨酸、踝臂指数的相关性。方法:将120例老年原发性高血压病患者按照有无合并AF发作分为两组:AF组为合并AF发作组65例;对照组为不合并AF发作(窦性心律组)55例,分别做血清同型半胱氨酸浓度和踝臂指数的检测,比较两组血清同型半胱氨酸水平、踝臂指数的高低。结果:高血压并AF组血清同型半胱氨酸浓度明显高于窦性心律组,踝臂指数小于窦性心律组,差异具有统计学意义(P〈0.05)。结论:高血压患者并AF发作有更高的血清同型半胱氨酸水平和更低的踝臂指数。 相似文献
7.
目的回顾分析心房颤动住院患者抗栓治疗情况,初步探讨心房颤动住院患者的病因组成、抗栓治疗现状。方法选择2008年1月~2009年7月住院的心房颤动患者120例,应用ACC/AHA/ESC心房颤动指南血栓栓塞危险分层标准对患者进行危险评估,对其病因、血栓栓塞危险因素、抗血栓药物应用情况及未应用华法林抗凝治疗原因进行分析。结果房颤的病因以冠心病、高血压病、老年退行性心瓣膜病、风湿性心瓣膜病及肺心病为主。对120例患者进行血栓栓塞危险评估,绝大多数合并多种危险因素,符合抗凝指征的患者82例,其中应用华法林者只有18例(21.9%),应用阿司匹林者35例(42.7%),其他抗血小板药物21例(25.6%),未应用抗血栓药物8例(9.7%)。结论冠心病、高血压病、老年退行性心脏瓣膜病等是房颤的主要病因。房颤患者华法林应用率低,依从性差,抗血小板药使用率高,患者抗栓治疗欠规范,需加强医生和患者抗栓治疗重要性和必要性的教育。 相似文献
8.
目的回顾分析心房颤动住院患者抗栓治疗情况,初步探讨心房颤动住院患者的病因组成、抗栓治疗现状。方法选择2008年1月~2009年7月住院的心房颤动患者120例.应用Acc/AHA/Esc心房颤动指南血栓栓塞危险分层标准对患者进行危险评估,对其病因、血栓栓塞危险因素、抗血栓药物应用情况及未应用华法林抗凝治疗原因进行分析。结果房颤的病因以冠心病、高血压病、老年退行性心瓣膜病、风湿性心瓣膜病及肺心病为主。对120例患者进行血栓栓塞危险评估,绝大多数合并多种危险因素,符合抗凝指征的患者82例,其中应用华法林者只有18例(21.9%),应用阿司匹林者35例(42.7%),其他抗血小板药物21例(25.6%),未应用抗血栓药物8例(9.7%)。结论冠心病、高血压病、老年退行性心脏瓣膜病等是房颤的主要病因。房颤患者华法林应用率低,依从性差,抗血小板药使用率高,患者抗栓治疗欠规范,需加强医生和患者抗栓治疗重要性和必要性的教育。 相似文献
9.
10.
《Journal of the American Medical Directors Association》2020,21(3):367-373.e1
ObjectivesNonagenarian patients are underrepresented in clinical trials that have evaluated oral anticoagulation in patients with atrial fibrillation (AF). The aim of this study was to assess the pronostic impact of oral anticoagulation in patients with AF age ≥90 years.DesignRetrospective multicenter study of nonagenarian patients with AF.Setting and participantsA total of 1750 nonagenarian inpatients and outpatients with nonvalvular AF between January 2013 and December 2018 in 3 Spanish health areas were studied.MethodsPatients were divided into 3 groups based on antithrombotic therapy: nonoral anticoagulants (30.5%), vitamin-K antagonists (VKAs; 28.6%), and direct oral anticoagulants (DOACs; 40.9%). During a mean follow-up of 23.6 ± 6.6 months, efficacy outcomes (death and embolic events) were evaluated using a Cox regression analysis and safety outcomes (bleeding requiring hospitalization) by competing-risk regression. Results were complemented with a propensity score matching analysis.ResultsDuring follow-up, 988 patients died (56.5%), 180 had embolic events (10.3%), and 186 had major bleeding (10.6%). After multivariable adjustment, DOACs were associated with a lower risk of death and embolic events than nonanticoagulation [hazard ratio (HR) 0.75, 95% confidence interval (CI)] 0.61‒0.92), but VKAs were not (HR 0.87, 95% CI 0.72‒1.05). These results were confirmed after propensity score matching analysis. For bleeding, both DOACs and VKAs proved to be associated with a higher risk (HR for DOAC 1.43; 95% CI 0.97‒2.13; HR for VKA 1.94; 95% CI 1.31‒2.88), although findings for DOACs were not statistically significant (P = .074). For intracranial hemorrhage (ICH), only VKAs—not DOACs—presented a higher risk of ICH (HR 4.43; 95% CI 1.48‒13.31).Conclusions and implicationsIn nonagenarian patients with AF, DOACs led to a reduction in mortality and embolic events in comparison with nonanticoagulation. This reduction was not observed with VKAs. Although both DOACs and VKAs increased the risk of bleeding, only VKAs were associated with higher ICH rates. 相似文献
11.
12.
13.
目的 对比研究普罗帕酮 (静脉和顿服 )与毛花甙C转复非瓣膜病心房颤动 (房颤 )的临床疗效和安全性。方法 房颤发作在 0 5h~ 41d的患者 97例 ,临床排除心脏瓣膜病、心力衰竭 (NYHA心功能≥III级 )、心肌梗死、病态窦房结综合症、II度以上房室传导阻滞、预激综合症及甲状腺机能亢进。随机分为三组 :⑴静脉普罗帕酮组 :共 3 3例 ,普罗帕酮 70mg于 7min内静注完 ,未转复者予 14 0mg以 0 5~ 1mg/min静滴。⑵顿服普罗帕酮组 :共 3 2例 ,顿服负荷量普罗帕酮 45 0mg。⑶静脉毛花甙C组 :共 3 2例 ,毛花甙C 0 4mg于 5min静注 ,若 4h仍未转复则追加 0 2mg。所有患者均在心电监护下观察心电、血压及症状变化 ,观察房颤转复及心室率的变化 ,记录从开始静脉推注或服药到转复为窦律的时间。比较三组患者 3 0min、1、2、4及 8h的转复率和转复时间。结果 三组平均转复时间 :静脉普罗帕酮组 ( 0 8± 0 4)h ,顿服普罗帕酮组 ( 4 1± 1 8)h ,静脉毛花甙C组 ( 3 7± 2 0 )h ,静脉普罗帕酮组与另两组差异有显著性 ( P <0 0 1)。三组 8h内转复率分别为 81 8%、75 0 %、68 8% ,差异无显著性 ( P =0 474>0 0 5 )。结论 上述两药三方法转复房颤 ,以静脉普罗帕酮平均转复时间最短 ,转复率最高 相似文献
14.
目的:分析血浆脑钠肽(BNP)水平在心房纤颤患者复律前、后中的变化,评价其临床应用价值。方法:选取2010年12月-2013年12月本院确诊为心房纤颤且成功复律的57例患者作为观察组,依据发作时间分为两亚组:阵发性房颤(发作时间〈2 d)31例,持续性房颤(持续发作2 d-12个月)26例;选取同期在本院行健康检查正常者33例作为对照组,分析观察组复律前后的血浆BNP水平变化。结果:观察组复律前的血浆BNP比对照组高,比较差异有统计学意义(P〈0.05);观察组两亚组的3项指标水平组间比较,差异差异有统计学意义(P〈0.05);观察组患者的BNP水平与LEVF呈负相关性,与LVEDD呈正相关性,比较差异有统计学意义(P〈0.05);观察组复律后、房颤复发患者的血浆BNP水平比对照组高,差异有统计学意义(P〈0.05);窦律维持患者的血浆BNP水平与对照组比较,差异无统计学意义(P〉0.05)。结论:心房纤颤患者复律前血浆脑钠肽水平明显升高,复律后其显著下降,可用于评价房颤患者的发作时间和治疗预后效果。 相似文献
15.
目的华法林抗凝治疗非瓣膜病性心房颤动(AF)患者的抗栓疗效和出血危险性。方法140例非瓣膜病性AF患者分为两组:治疗组74例,服用华法林服用从1.5mg开始,1次/d,根据血浆凝血酶原时间国际标准化比率(INR)调整华法林剂量,INK达标为2.0—3.0,持续服药,并随访1年;对照组66例,持续服安慰剂,并随访1年。观察两组栓塞事件及出血发生率。结果治疗组栓塞事件及出血发生率分剐为o%和2.7%,对照组栓塞事件及出血发生率分别为4.5%和0%。两组比较差畀均有统计学意义(P〈0.01)。结论华法林抗凝治疗非瓣膜病性AF患者,华法林抗凝目标INK值在2。0—3.0是安全有效。 相似文献
16.
《Hospital practice (1995)》2013,41(4):153-162
AbstractFour non-vitamin-K antagonist oral anticoagulants (NOACs) are now available and are variously approved for stroke prevention in atrial fibrillation and the management of venous thromboembolism. On the whole, these drugs offer clear benefits over warfarin, overcoming problems with unpredictable individual responses and avoiding the need for frequent and resource-intensive monitoring. Sufficient data are now available to recommend the use of particular NOACs in defined settings. As a group these drugs offer a real alternative to warfarin; their more widespread use for stroke prevention in atrial fibrillation, in the management of venous thromboembolism, and perhaps in other settings promises to bring real clinical gains for at-risk populations worldwide. This review highlights the growing importance of effective anticoagulation therapy at a time when cardiovascular risk profiles are evolving, discusses the relative merits of the NOACs over warfarin, and describes the use of specific agents in specific patient populations. 相似文献
17.
目的 探讨华法令对于非瓣膜病性心房颤动患者抗凝治疗的临床效果 ,摸索出深圳地区NVAF患者华法令抗凝治疗的有效安全剂量。 方法 对符合本研究标准的 74例老年心房颤动患者随机分为华法令治疗组和阿司匹林对照组 ,华法令治疗组 3 6例 ,给予华法令 3mg/d开始 ,监测凝血酶原时间 (PT )及国际标准化比值 (INR) ,连续观察 4周使INR在 2 .0~ 3 .0范围内 ,以后每月查 1次INR。若病人需增加或减少药物或有出血倾向时随时再测INR ;阿司匹林对照组 3 8例 ,给予阿司匹林 3 0 0mg/d ,分 2次服用。 结果 华法令治疗组PT监测 ,第 1、2、4、8周 ,均较用药前有显著性差异 (P <0 .0 5 ) ;随访期间 ,华法令治疗组脑卒中的发生率为 2 .8% ,阿司匹林对照组为 13 .2 % ,两组比较有显著性差异 (P<0 .0 5 ) ;两组均未见明显的出血等副作用。 结论 深圳地区非瓣膜病性心房颤动患者选择华法令 3~ 4mg/d抗凝治疗是安全有效的。 相似文献
18.
目的:了解社区65岁及以上老年房颤患者抗凝治疗和社区随访情况,为进一步规范抗凝治疗提供理论基础和建议.方法:采用回顾性分析方法,入选2017-2018年本社区65岁及以上老年人心电图或动态心电图诊断房颤的166例患者,通过查阅居民电子健康档案、门诊随访和电话随访方式,记录性别、年龄、主要疾病诊断、CHA2DS2-VAS... 相似文献
19.
《Value in health》2015,18(2):234-249
ObjectivesTo critically appraise published network meta-analyses (NMAs) evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, rivaroxaban, and apixaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF).MethodsA systematic literature review was performed to identify the relevant NMAs using MEDLINE, EMBASE, Cochrane Library, Database of Abstracts of Reviews of Effects, and Health Technology Assessment. The synthesis studies were evaluated using the “Questionnaire to assess the relevance and credibility of the NMA.”ResultsEleven NMAs evaluating NOACs among adults with nonvalvular AF were identified. Most NMAs included three large phase III randomized controlled trials, comparing NOACs to adjusted-dose warfarin (Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY], Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF], and Apixaban for Reduction of Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]). The main differences identified related to potential treatment effect modifiers regarding the mean time spent in therapeutic range (TTR) in the warfarin arm, the risk of stroke or systemic embolism across the trials (mean CHADS2 score: C = congestive heart failure, H = hypertension, A = older than age 75 years, D = diabetes mellitus, S2 = prior stroke or history of transient ischemic attack) or primary versus secondary prevention, and type of populations used in the analysis. Kansal et al. [Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness. Thromb Haemost 2012;108:672–82] appropriately adjusted the ROCKET-AF TTR to match the RE-LY population on the basis of individual patient data. Meta-regressions are not expected to minimize confounding bias given limited data, whereas subgroup analyses had some impact on the point estimates for the treatment comparisons.ConclusionsResults of the synthesis studies were generally comparable and suggested that the NOACs had similar efficacy, although some differences were identified depending on the outcome. The extent to which differences in the distribution of TTR, CHADS2 score, or primary versus secondary prevention biased the results remains unclear. 相似文献
20.
目的通过检测房颤及不同心室率控制水平的房颤患者血清高敏C反应蛋白(hsCRP)水平与左心房(LA)直径,评价控制房颤患者心室率对于降低血清hsCRP,减少心脑血管并发症的临床意义。方法选取非阵发性心房颤动患者97人,依据静息心室率控制情况分为三组:房颤1组(静息心室率60次/分~79次/分);房颤2组(静息心室率80次/分~109次/分);房颤3组(静息心室率大于等于110次/分)。选取同期窦性心律的健康体检人群38人作为对照组。测定四组人群血清hsCRP和LA直径。结果与对照组相比,房颤组hsCRP和LA直径均增高,差异有统计学意义。房颤3组hsCRP及LA直径较房颤1组、房颤2组升高(P值分别为0.027,0.046,0.035,0.041),房颤1组与房颤2组两组间hsCRP及LA直径无统计学差异。线性相关分析显示血清hsCRP与LA直径、心率相关(相关系数分别为0.179、0.350,P值分别为0.026、0.022)。结论血清hsCRP及左心房直径在房颤及心室率控制欠佳的房颤患者中明显增高,控制房颤患者心室率能减轻心肌重构、降低hsCRP水平。 相似文献